Payment overview · 2025
General Payments
$110.79
6 reported records · 5 companies
Healthcare provider profile · identity verified
Manisha Tiwari, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · TARBORO, NC · NPI 1265786115
Verified facts
What the public records show
CMS Open Payments records show Manisha Tiwari, M.D. received $110.79 in general payments during 2025 across 6 reported records.
Novo Nordisk Inc accounted for 39.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Prolia by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 242 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $43.73 | 39.5% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $21.34 | 19.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.41 | 13.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.31 | 13.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.00 | 13.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $110.79 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $25.36 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $21.34 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.37 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.37 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.41 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 242 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 66 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
84 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
242 | 44 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
66 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
84 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1670 | 365 |
| Amlodipine Besylate | Amlodipine Besylate | 1204 | 267 |
| Omeprazole | Omeprazole | 844 | 180 |
| Losartan Potassium | Losartan Potassium | 673 | 141 |
| Gabapentin | Gabapentin | 613 | 123 |
| Metformin Hcl | Metformin Hcl | 552 | 106 |
| Levothyroxine Sodium | Levothyroxine Sodium | 535 | 101 |
| Valsartan | Valsartan | 481 | 80 |
| Atenolol | Atenolol | 416 | 77 |
| Lisinopril | Lisinopril | 406 | 101 |
| Furosemide | Furosemide | 360 | 85 |
| Pantoprazole Sodium | Pantoprazole Sodium | 357 | 71 |
| Montelukast Sodium | Montelukast Sodium | 341 | 80 |
| Carvedilol | Carvedilol | 316 | 66 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 305 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 293 | 75 |
| Pravastatin Sodium | Pravastatin Sodium | 278 | 58 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 260 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 252 | 61 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 249 | 95 |
| Hydralazine Hcl | Hydralazine Hcl | 243 | 40 |
| Ozempic | Semaglutide | 242 | 44 |
| Metformin Hcl Er | Metformin Hcl | 233 | 55 |
| Potassium Chloride | Potassium Chloride | 217 | 59 |
| Fluticasone Propionate | Fluticasone Propionate | 197 | 77 |
| Ezetimibe | Ezetimibe | 191 | 36 |
| Allopurinol | Allopurinol | 184 | 36 |
| Spironolactone | Spironolactone | 176 | 48 |
| Trazodone Hcl | Trazodone Hcl | 161 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 159 | 31 |
| Tradjenta | Linagliptin | 156 | 21 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 151 | 34 |
| Sertraline Hcl | Sertraline Hcl | 151 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 151 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 146 | 30 |
| Jardiance | Empagliflozin | 145 | 27 |
| Simvastatin | Simvastatin | 144 | 34 |
| Glipizide Er | Glipizide | 138 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 137 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 126 | 28 |
| Lovastatin | Lovastatin | 126 | 28 |
| Januvia | Sitagliptin Phosphate | 122 | 25 |
| Alendronate Sodium | Alendronate Sodium | 117 | 30 |
| Famotidine | Famotidine | 116 | 28 |
| Glimepiride | Glimepiride | 108 | 24 |
| Pregabalin | Pregabalin | 107 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 106 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 99 | 17 |
| Nifedipine Er | Nifedipine | 98 | 16 |
| Buspirone Hcl | Buspirone Hcl | 97 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 95 | 46 |
| Colchicine | Colchicine | 93 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 90 | 23 |
| Chlorthalidone | Chlorthalidone | 87 | 23 |
| Donepezil Hcl | Donepezil Hcl | 85 | 14 |
| Glipizide | Glipizide | 85 | 20 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 85 | 14 |
| Eliquis | Apixaban | 84 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 80 | 22 |
| Meloxicam | Meloxicam | 80 | 32 |
| Tizanidine Hcl | Tizanidine Hcl | 72 | 16 |
| Meclizine Hcl | Meclizine Hcl | 70 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 68 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 68 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 67 | 17 |
| Benazepril Hcl | Benazepril Hcl | 66 | 16 |
| Rybelsus | Semaglutide | 66 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 65 | 28 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 64 | 38 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 63 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 62 | 12 |
| Linzess | Linaclotide | 62 | 17 |
| Symbicort | Budesonide/Formoterol Fumarate | 61 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 59 | 18 |
| Tramadol Hcl | Tramadol Hcl | 59 | 25 |
| Clonidine Hcl | Clonidine Hcl | 58 | 12 |
| Alprazolam | Alprazolam | 55 | 16 |
| Naproxen | Naproxen | 55 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 54 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 53 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 52 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 51 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 51 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 50 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | suppressed |
| Trulicity | Dulaglutide | 47 | suppressed |
| Baclofen | Baclofen | 42 | suppressed |
| Ciclopirox | Ciclopirox | 40 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 40 | 12 |
| Mirtazapine | Mirtazapine | 39 | suppressed |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Bumetanide | Bumetanide | 37 | suppressed |
| Lansoprazole | Lansoprazole | 37 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | suppressed |
| Klor-Con M20 | Potassium Chloride | 35 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 34 | 21 |
| Lorazepam | Lorazepam | 34 | 16 |
| Dexlansoprazole Dr | Dexlansoprazole | 33 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 33 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 28 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 28 | suppressed |
| Acarbose | Acarbose | 27 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 27 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Lactulose | Lactulose | 27 | 18 |
| Bupropion Hcl | Bupropion Hcl | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Felodipine Er | Felodipine | 26 | suppressed |
| Ketoconazole | Ketoconazole | 26 | 11 |
| Nateglinide | Nateglinide | 26 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 25 | 11 |
| Prednisone | Prednisone | 25 | 22 |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 25 | suppressed |
| Clonazepam | Clonazepam | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 24 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 15 |
| Sucralfate | Sucralfate | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Calcitriol | Calcitriol | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Phenobarbital | Phenobarbital | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 20 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Febuxostat | Febuxostat | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | 13 |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 16 | suppressed |
| Kerendia | Finerenone | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Prolia | Denosumab | 16 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Nexium | Esomeprazole Magnesium | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 15 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Humalog Mix 50-50 Kwikpen | Insulin Lispro Protamin/Lispro | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Enulose | Lactulose | 13 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Leflunomide | Leflunomide | 13 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Nyamyc | Nystatin | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Famciclovir | Famciclovir | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Isosorbide Dinit-Hydralazine | Isosorbide Dinit/Hydralazine | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Procto-Med Hc | Hydrocortisone | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Victoza 3-Pak | Liraglutide | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Azathioprine | Azathioprine | 11 | suppressed |
| Desipramine Hcl | Desipramine Hcl | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $110.79 · 6 records | Novo Nordisk Inc | ABRYSVO, CAMZYOS, COMIRNATY, OTEZLA, Ozempic, PREVNAR 20, REPATHA, Rybelsus, TRELEGY ELLIPTA, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error